Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BGB-16673 + mosunetuzumab
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
BGB-16673 + mosunetuzumab is a combination of two agents under investigation for B-cell malignancies. **BGB-16673** is an orally available, small-molecule chimeric degradation activation compound that targets and degrades Bruton's tyrosine kinase (BTK), disrupting B-cell receptor signaling and overcoming resistance due to BTK mutations[4][7]. **Mosunetuzumab** is a humanized, bispecific monoclonal antibody that binds CD20 (on B cells) and CD3 (on T cells), redirecting T-cell cytotoxicity toward malignant B cells[2][5]. The drugs are in clinical trial settings for relapsed or refractory B-cell lymphomas, including chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia (WM), and follicular lymphoma. Mosunetuzumab is already approved as monotherapy for relapsed or refractory follicular lymphoma after two prior therapies[2][5].
- Brand names
- Lunsumio
- Other names
- mosunetuzumabBGB-16673BGB16673BGB 16673
02
Targets
CRBN (Cereblon)BTK (Bruton tyrosine kinase)CD20 (B-lymphocyte antigen CD20)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on BGB-16673 + mosunetuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BGB-16673 + mosunetuzumab.